Launch of India’s First Non-Antibiotic UTI Drug by Cipla Limited
Published: 10 Mar 2026
Author: Precedence Research
Cipla Limited has introduced Methenamine Hippurate, a non-antibiotic therapy for individuals suffering from recurrent urinary tract infections (UTIs). Marketed under the brand name HUENA, the drug marks a significant step in the company’s strategy to combat rising antimicrobial resistance (AMR) while expanding access to preventive treatments in India. The launch is particularly notable as it represents one of the first widely available non-antibiotic UTI preventive options in the country, addressing a growing public health concern.
Addressing the Growing Burden of Urinary Tract Infections in India
Urinary tract infections are among the most common bacterial infections globally and represent a significant healthcare burden in India. According to clinical observations and healthcare data, UTIs are the second most common reason for antibiotic prescriptions, placing considerable pressure on antimicrobial stewardship efforts. Infection rates in the country have nearly doubled over the past three decades, reflecting changes in lifestyle, increasing antibiotic resistance, and greater diagnostic awareness.
Women are particularly vulnerable to UTIs due to anatomical and hormonal factors. Medical studies estimate that over half of all women experience at least one UTI during their lifetime, and a substantial proportion suffer from recurrent infections that require repeated courses of antibiotics. Such repeated exposure to antibiotics can accelerate the development of drug-resistant bacteria, making infections more difficult to treat over time.
The newly launched Methenamine Hippurate works differently from traditional antibiotics. Instead of directly killing bacteria, it converts into formaldehyde in the acidic environment of the urinary tract, creating conditions that inhibit bacterial growth. This mechanism helps prevent infection recurrence without contributing to antibiotic resistance. Clinical studies have shown that the therapy can be as effective as long-term, low-dose antibiotic regimens for preventing recurrent UTIs, while also offering a safer alternative for long-term use.
Market Growth and Demand for Non-Antibiotic Therapies
The launch also aligns with broader trends in the global UTI therapeutics landscape. According to Precedence Research, the UTI Drugs Market size accounted for USD 5.06 billion in 2025 and is predicted to increase from USD 5.34 billion in 2026 to approximately USD 8.65 billion by 2035, expanding at a CAGR of 5.50% from 2026 to 2035. Market expansion is being driven by the rising incidence of UTIs, improved diagnostic technologies, and the growing need for innovative therapies that reduce dependence on antibiotics.
Pharmaceutical companies are increasingly focusing on non-antibiotic treatment strategies, preventive therapies, and targeted drug delivery systems. These developments are expected to reshape how recurrent infections are managed, particularly in regions with high antibiotic consumption such as India.
Leadership Perspective on the Innovation
Reflecting on the milestone, Achin Gupta stated that the launch represents a strong commitment to antimicrobial stewardship and innovation in infection management.
“The launch of HUENA shows our strong commitment to antimicrobial stewardship and addressing the growing problem of AMR. We believe this innovation will greatly improve patient outcomes while reducing reliance on antibiotics, thus promoting a healthier future for all.”
Similarly, Dr. Jaideep Gogtay emphasized the urgency of addressing antimicrobial resistance through new therapeutic strategies.
“At Cipla, we recognize the urgent need for new strategies to tackle the rising challenge of AMR. This groundbreaking launch provides patients with a non-antibiotic treatment that will help prevent urinary tract infections without worsening antimicrobial resistance.”
Expanding Innovation in the UTI Therapeutics Landscape
The introduction of HUENA signals a broader shift within the pharmaceutical industry toward preventive and resistance-conscious treatment approaches. Non-antibiotic therapies are gaining traction as healthcare providers seek solutions that reduce repeated antibiotic exposure while maintaining effective disease management.
A recent report by Precedence Research highlights that the UTI drug market is benefiting from rising research and development investments, improved diagnostic technologies, and the rapid emergence of non-antibiotic therapeutic options. As awareness of antimicrobial resistance continues to grow, innovations like Methenamine Hippurate are expected to play a key role in shaping the future of infection management and strengthening global public health strategies.